Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Glioblastoma Multiforme Treatment Market

Glioblastoma Multiforme Treatment Market Trends

Report ID: GMI9866
Published Date: Jun 2024
Report Format: PDF

Download Free Sample

Glioblastoma Multiforme Treatment Market Trends

The increasing prevalence of glioblastoma significantly drives the growth of the market. For instance, as per the report published by the National Brain Tumor Society, it has been reported that glioblastoma (GBM) is one of the most complex, deadly, and treatment-resistant cancers. Also, the report stated that the five-year survival rate for glioblastoma patients is only 6.9%, and the average length of survival for glioblastoma patients is estimated to be only 8 months. Therefore, the high prevalence of glioblastoma necessitates an increasing demand for better treatment options, thereby driving the market growth.
Moreover, the growing patient population necessitates more comprehensive healthcare infrastructure and supportive services. Also, pharmaceutical companies are incentivized to invest in innovative solutions, fostering competitive dynamics that enhance the quality and availability of glioblastoma multiforme treatments.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Global glioblastoma multiforme treatment industry was valued at USD 2.9 billion in 2023 and is anticipated to register 8.6% CAGR between 2024 and 2032 due to the increasing incidence of glioblastoma along with rising awareness and early diagnosis of disease.

The hospitals segment in the market is expected to reach USD 2.5 billion by 2032 due to presence of advanced diagnostic tools, specialized neuro-oncology departments, and clinical trials.

North America glioblastoma multiforme treatment market held 39.5% revenue share in 2023 due to advanced technologies, key pharmaceutical companies, and government cancer research funding.

Amgen Inc., Amneal Pharmaceuticals, Curtana Pharmaceuticals, Denovo Biopharma, Eisai Co. Ltd. (Gliadel), F. Hoffmann La Roche Ltd (Genetech USA), Karyopharm Therapeutics, Merck & Co. Inc., and Novocure GmbH, among others.